ClinicalTrials.gg
TerminatedNCT05088460LEAPUpdated Oct 16, 2025Results posted

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

A Phase 2 interventional study of REGN4461 and Matching Placebo in Familial Partial Lipodystrophy and Metabolic Abnormalities, sponsored by Regeneron Pharmaceuticals. Terminated at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lipodystrophy, Familial Partial with a site in United States — 2 open to participants now, 2 under way, 2 of them phase 3. Lipodystrophy, Familial Partial · United States.

Enrollment
4th of 10
20 · median 12
Started
2022
the only one that year
Phase 2
4 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
3 of 11
Regeneron Pharmaceuticals

Among the 11 studies in Lipodystrophy, Familial Partial with a site in United States, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 4 in phase 2, and was the 8th registered.

Lipodystrophy, Familial Partial

20 studies on the registry are indexed under Lipodystrophy, Familial Partial; 5 are open to participants now.

Browse Lipodystrophy, Familial Partial studies →

Open to participants now

2 of the 11 studies in Lipodystrophy, Familial Partial with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Lipodystrophy, Familial Partial studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lipodystrophy, Familial Partial with a site in United States, or all of them as a file.
02

Study summary

Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin \<8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL

The primary objectives will be evaluated for patients in Cohort A only:

  • To evaluate the effect of REGN4461 on fasting triglycerides (TG) in patients with elevated baseline fasting TG
  • To evaluate the effect of REGN4461 on hyperglycemia in patients with elevated baseline Hemoglobin A1c (HbA1c)

The following secondary objectives of the study will be evaluated for Cohort B and for the combined set of Cohorts A plus B:

  • To evaluate the effect of REGN4461 on fasting TG levels in patients with hypertriglyceridemia
  • To evaluate the effect of REGN4461 on glycemic control in patients with hyperglycemia

The following secondary objectives of the study will be evaluated for Cohorts A and B separately, and for the combined set of Cohorts A plus B:

  • To evaluate the effect of REGN4461 on liver fat in patients with hepatic steatosis
  • To evaluate the effect of REGN4461 on hunger
  • To evaluate safety and tolerability of REGN4461
  • To characterize the concentration profile of REGN4461 over time
  • To assess immunogenicity to REGN4461
03

Conditions studied

  • Familial Partial Lipodystrophy
  • Metabolic Abnormalities
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of familial partial lipodystrophy as defined in the protocol
  • Fasting leptin level ≤20.0 ng/ml, as determined during the screening period
  • Presence of significant metabolic abnormalities related to glucose and triglycerides (TGs) as defined in the protocol
  • Stable body weight within the 3 months prior to screening (no gain or loss of >5% current weight)
  • Stable diet during the past 3 months defined as no major change in macronutrient composition (eg, starting or stopping diets such as Atkins, Paleo, Vegetarianism, Veganism)
  • No change in medication regimen in the 3 months prior to screening as defined in the protocol

Key Exclusion Criteria:

  • Treatment with metreleptin within 3 months of the screening visit
  • Patients with a diagnosis of generalized lipodystrophy
  • Patients with a diagnosis of acquired lipodystrophy
  • Pregnant or breastfeeding women

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Study Arm 1

    Randomized to placebo for 12 weeks and then crossover to REGN4461 for 12 weeks

    Drug: REGN4461 · Drug: Matching Placebo

  • Experimental
    Study Arm 2

    Randomized to receive REGN4461 for 24 weeks

    Drug: REGN4461

Interventions

  • Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).

    Also known as: mibavademab

  • DrugMatching Placebo

    Intravenous (IV) infusion loading dose followed by subcutaneous (SC) injection weekly (QW).

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A)

    Percentage change in fasting serum TG was reported for participants with elevated baseline fasting TG (\> 200 mg/dL) and with baseline leptin \< 8.0 ng/mL (Cohort A).

    Time frame: Baseline to week 12

  2. Change From Baseline to Week 12 in Hemoglobin A1c (HbA1c) (Cohort A)

    Change in HbA1c was reported for participants with elevated baseline HbA1c (\> 7.0%) and with baseline leptin \< 8.0 ng/mL (Cohort A).

    Time frame: Baseline to week 12

Secondary outcomes

  1. Percent Change From Baseline to Week 12 in Fasting Serum TG (Cohorts B and A + B)

    Percent change in fasting serum TG was reported for participants with elevated baseline fasting TG (\>200 mg/dL) in Cohort B and Cohorts A + B.

    Time frame: Baseline to week 12

  2. Change From Baseline to Week 12 in HbA1c (Cohorts B and A + B)

    Change in HbA1c was reported for participants with elevated baseline HbA1c (\>7.0%) in Cohort B and Cohorts A + B.

    Time frame: Baseline to week 12

  3. Percent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 1)

    Percent change in fasting serum TG was reported for participants in Study Arm 1.

    Time frame: Baseline, Week 12, Week 24

  4. Percent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 2)

    Percent change in fasting serum TG was reported for participants in Study Arm 2.

    Time frame: Baseline, Week 12, Week 24

  5. Change From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 1)

    Change from baseline in HbA1c was reported for participants in Study Arm 1.

    Time frame: Baseline, Week 12, Week 24

  6. Change From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 2)

    Change from baseline in HbA1c was reported for participants in Study Arm 2.

    Time frame: Baseline, Week 12, Week 24

  7. Change From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 1)

    Change from baseline in fasting glucose was reported for participants in Study Arm 1.

    Time frame: Baseline, Week 12, Week 24

  8. Change From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 2)

    Change from baseline in fasting glucose was reported for participants in Study Arm 2.

    Time frame: Baseline, Week 12, Week 24

  9. Percent Change From Baseline to Weeks 12 and 24 in Liver Fat Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF) (Study Arm 1)

    Percent change from baseline in MRI-PDFF was reported for participants with baseline MRI-PDFF ≥8.5% in Study Arm 1.

    Time frame: Baseline, Week 12, Week 24

  10. Percent Change From Baseline to Weeks 12 and 24 in Liver Fat MRI-PDFF (Study Arm 2)

    Percent change from baseline in MRI-PDFF was reported for participants with baseline liver fat MRI-PDFF ≥8.5% in Study Arm 2.

    Time frame: Baseline, Week 12, Week 24

  11. Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Highest Hunger Score

    The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The highest hunger score asked participants to rate their highest hunger that day on a scale from 0 to 4, with higher scores representing the higher perceived hunger. A negative change from baseline indicated a reduction in perceived hunger.

    Time frame: Baseline, Week 12, Week 24

  12. Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Lowest Hunger Score

    The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The lowest hunger score asked participants to rate their lowest hunger that day on a scale from 0 to 4, with higher scores indicating higher perceived hunger. A negative change from baseline score indicated a reduction in perceived lowest hunger.

    Time frame: Baseline, Week 12, Week 24

  13. Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Felt Hungry Score

    The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among participants with lipodystrophy. The felt hungry score asked how much time participants felt hunger that day on a scale from 0 to 4, with higher scores indicating more time feeling hungry. A negative change from baseline score indicated a reduction in time spent feeling hungry.

    Time frame: Baseline, Week 12, Week 24

  14. Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Fullness Score

    The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The fullness score asked participants to rate how often they felt full after eating that day on a scale from 0 to 4, with higher scores indicating higher feeling of fullness. A negative change from baseline indicated a reduced feeling of fullness.

    Time frame: Baseline, Week 12, Week 24

  15. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Day 169

  16. Concentrations of REGN4461 in Serum

    Time frame: Weeks 0, 1, 2, 3, 4, 5, 6, 9, 12, 13, 14, 15, 16, 17, 18, 21, 28, 32 and 36. Weeks 0 and 12 collected pre- and post-dose. All other time points were only pre-dose.

  17. Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response

    Time frame: Up to Day 281

07

Results

Posted Jul 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461
Started6644
Completed treatment during dbtp5644
Completed treatment during sbtp5534
Completed6644
Not completed0000

Outcome measures

PrimaryPercent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A)

Percentage change in fasting serum TG was reported for participants with elevated baseline fasting TG (\> 200 mg/dL) and with baseline leptin \< 8.0 ng/mL (Cohort A).

Time frame:
Baseline to week 12
Reported as:
Mean · percent change
Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A)
percent changeArm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461
Percent Change From Baseline to Week 12 in Fasting Serum Triglyceride (TG) (Cohort A)-11.30 ± 46.306-38.97 ± 16.998
PrimaryChange From Baseline to Week 12 in Hemoglobin A1c (HbA1c) (Cohort A)

Change in HbA1c was reported for participants with elevated baseline HbA1c (\> 7.0%) and with baseline leptin \< 8.0 ng/mL (Cohort A).

Time frame:
Baseline to week 12
Reported as:
Mean · percentage of glycated hemoglobin
Change From Baseline to Week 12 in Hemoglobin A1c (HbA1c) (Cohort A)
percentage of glycated hemoglobinArm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461
Change From Baseline to Week 12 in Hemoglobin A1c (HbA1c) (Cohort A)-0.05 ± 0.451-1.08 ± 1.108
SecondaryPercent Change From Baseline to Week 12 in Fasting Serum TG (Cohorts B and A + B)

Percent change in fasting serum TG was reported for participants with elevated baseline fasting TG (\>200 mg/dL) in Cohort B and Cohorts A + B.

Time frame:
Baseline to week 12
Reported as:
Mean · percent change
Percent Change From Baseline to Week 12 in Fasting Serum TG (Cohorts B and A + B)
percent changeArm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Percent Change From Baseline to Week 12 in Fasting Serum TG (Cohorts B and A + B)36.78 ± 44.863-35.59 ± 8.75410.07 ± 49.689-37.62 ± 13.752
SecondaryChange From Baseline to Week 12 in HbA1c (Cohorts B and A + B)

Change in HbA1c was reported for participants with elevated baseline HbA1c (\>7.0%) in Cohort B and Cohorts A + B.

Time frame:
Baseline to week 12
Reported as:
Mean · percentage of glycated hemoglobin
Change From Baseline to Week 12 in HbA1c (Cohorts B and A + B)
percentage of glycated hemoglobinArm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Change From Baseline to Week 12 in HbA1c (Cohorts B and A + B)-0.20 ± 0.283-0.90 ± 0.964-0.10 ± 0.379-1.01 ± 0.988
SecondaryPercent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 1)

Percent change in fasting serum TG was reported for participants in Study Arm 1.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 1)
percent changeArm 1 Cohort A: Placebo to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461
Week 12-11.30 ± 46.30636.78 ± 44.86310.07 ± 49.689
Week 24-29.79 ± 35.109-8.96 ± 13.673-23.84 ± 30.923
SecondaryPercent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 2)

Percent change in fasting serum TG was reported for participants in Study Arm 2.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Weeks 12 and 24 in Fasting Serum TG (Study Arm 2)
percent changeArm 2 Cohort A: REGN4461 to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 12-38.97 ± 16.998-35.59 ± 8.754-37.62 ± 13.752
Week 24-30.77 ± 48.883-5.30 ± 51.158-18.04 ± 48.282
SecondaryChange From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 1)

Change from baseline in HbA1c was reported for participants in Study Arm 1.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percentage of glycated hemoglobin
Change From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 1)
percentage of glycated hemoglobinArm 1 Cohort A: Placebo to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461
Week 12-0.10 ± 0.4060.13 ± 0.4270.00 ± 0.406
Week 24-0.78 ± 0.6940.13 ± 0.802-0.44 ± 0.826
SecondaryChange From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 2)

Change from baseline in HbA1c was reported for participants in Study Arm 2.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percentage of glycated hemoglobin
Change From Baseline to Weeks 12 and 24 in HbA1c (Study Arm 2)
percentage of glycated hemoglobinArm 2 Cohort A: REGN4461 to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 12-0.92 ± 1.068-0.78 ± 0.826-0.86 ± 0.931
Week 24-0.98 ± 1.357-0.50 ± 1.068-0.77 ± 1.188
SecondaryChange From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 1)

Change from baseline in fasting glucose was reported for participants in Study Arm 1.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 1)
milligrams per deciliter (mg/dL)Arm 1 Cohort A: Placebo to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461
Week 124.8 ± 29.550.0 ± 60.372.7 ± 42.54
Week 247.2 ± 29.65-15.5 ± 6.360.7 ± 26.75
SecondaryChange From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 2)

Change from baseline in fasting glucose was reported for participants in Study Arm 2.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · mg/dL
Change From Baseline to Weeks 12 and 24 in Fasting Glucose (Study Arm 2)
mg/dLArm 2 Cohort A: REGN4461 to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 12-5.2 ± 36.55-19.5 ± 22.87-10.9 ± 31.17
Week 241.8 ± 26.35-12.3 ± 58.59-5.3 ± 42.71
SecondaryPercent Change From Baseline to Weeks 12 and 24 in Liver Fat Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF) (Study Arm 1)

Percent change from baseline in MRI-PDFF was reported for participants with baseline MRI-PDFF ≥8.5% in Study Arm 1.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Weeks 12 and 24 in Liver Fat Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF) (Study Arm 1)
percent changeArm 1 Cohort A: Placebo to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461
Week 12-11.44 ± 18.576-0.74 ± 9.919-7.16 ± 15.214
Week 24-47.21 ± 22.17644.81 ± NA-16.54 ± 55.394
SecondaryPercent Change From Baseline to Weeks 12 and 24 in Liver Fat MRI-PDFF (Study Arm 2)

Percent change from baseline in MRI-PDFF was reported for participants with baseline liver fat MRI-PDFF ≥8.5% in Study Arm 2.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Weeks 12 and 24 in Liver Fat MRI-PDFF (Study Arm 2)
percent changeArm 2 Cohort A: REGN4461 to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 12-17.05 ± 25.788-18.80 ± 17.300-17.92 ± 20.351
Week 24-24.33 ± 27.151-19.53 ± 19.324-22.27 ± 22.353
SecondaryChange From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Highest Hunger Score

The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The highest hunger score asked participants to rate their highest hunger that day on a scale from 0 to 4, with higher scores representing the higher perceived hunger. A negative change from baseline indicated a reduction in perceived hunger.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Highest Hunger Score
score on a scaleArm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 12-0.060 ± 0.9009-0.538 ± 0.4679-0.240 ± 0.2483-0.415 ± 0.7539-0.132 ± 0.6929-0.489 ± 0.5614
Week 24-0.330 ± 0.3684-0.018 ± 0.6228-0.383 ± 0.1550-0.285 ± 0.6180-0.350 ± 0.2919-0.137 ± 0.5975
SecondaryChange From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Lowest Hunger Score

The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The lowest hunger score asked participants to rate their lowest hunger that day on a scale from 0 to 4, with higher scores indicating higher perceived hunger. A negative change from baseline score indicated a reduction in perceived lowest hunger.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Lowest Hunger Score
score on a scaleArm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 120.185 ± 0.8013-0.475 ± 0.4630-0.338 ± 0.4287-0.173 ± 0.3625-0.024 ± 0.7006-0.354 ± 0.4328
Week 24-0.128 ± 0.06220.046 ± 0.6776-0.103 ± 0.22300.308 ± 0.9603-0.119 ± 0.12880.162 ± 0.7710
SecondaryChange From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Felt Hungry Score

The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among participants with lipodystrophy. The felt hungry score asked how much time participants felt hunger that day on a scale from 0 to 4, with higher scores indicating more time feeling hungry. A negative change from baseline score indicated a reduction in time spent feeling hungry.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Felt Hungry Score
score on a scaleArm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 120.248 ± 0.8642-0.550 ± 0.5334-0.168 ± 0.29000.008 ± 0.91390.082 ± 0.6993-0.327 ± 0.7206
Week 240.016 ± 0.39320.120 ± 0.4374-0.183 ± 0.0603-0.138 ± 0.6595-0.059 ± 0.31630.006 ± 0.5265
SecondaryChange From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Fullness Score

The daily lipodystrophy hunger questionnaire was developed to assess hunger related behaviors among patients with lipodystrophy. The fullness score asked participants to rate how often they felt full after eating that day on a scale from 0 to 4, with higher scores indicating higher feeling of fullness. A negative change from baseline indicated a reduced feeling of fullness.

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · score on a scale
Change From Baseline to Weeks 12 and 24 on the Daily Lipodystrophy Hunger Questionnaire - Fullness Score
score on a scaleArm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Arm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 120.063 ± 1.1988-0.267 ± 0.5381-1.180 ± 0.3764-0.535 ± 0.5736-0.434 ± 1.1216-0.374 ± 0.5383
Week 24-0.182 ± 0.64740.012 ± 0.6474-1.193 ± 0.6630-0.178 ± 0.8032-0.561 ± 0.7994-0.072 ± 0.6793
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame:
Up to Day 169
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsDBTP Arm 1 Cohort A: PlaceboDBTP Arm 2 Cohort A: REGN4461DBTP Arm 1 Cohort B: PlaceboDBTP Arm 2 Cohort B: REGN4461DBTP Arm 1 Combined Cohort A + B: PlaceboDBTP Arm 2 Combined Cohort A + B: REGN4461SBTP Arm 1 Cohort A: Placebo to REGN4461SBTP Arm 2 Cohort A: REGN4461 to REGN4461SBTP Arm 1 Cohort B: Placebo to REGN4461SBTP Arm 2 Cohort B: REGN4461 to REGN4461SBTP Arm 1 Combined Cohort A + B: Placebo to REGN4461SBTP Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Number of Participants With Treatment-emergent Adverse Events (TEAEs)454489353469
SecondaryConcentrations of REGN4461 in Serum
Time frame:
Weeks 0, 1, 2, 3, 4, 5, 6, 9, 12, 13, 14, 15, 16, 17, 18, 21, 28, 32 and 36. Weeks 0 and 12 collected pre- and post-dose. All other time points were only pre-dose.
Reported as:
Mean · milligrams per liter (mg/L)
Concentrations of REGN4461 in Serum
milligrams per liter (mg/L)Arm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Week 0 (pre-dose)0 ± 00 ± 0
Week 0 (post-dose)0 ± 0232 ± 83.8
Week 1 (pre-dose)0 ± 064.3 ± 24.9
Week 2 (pre-dose)0 ± 052.5 ± 13.3
Week 3 (pre-dose)0 ± 060.2 ± 19.0
Week 4 (pre-dose)0 ± 058.8 ± 23.8
Week 5 (pre-dose)0 ± 062.0 ± 36.1
Week 6 (pre-dose)0 ± 068.8 ± 38.8
Week 9 (pre-dose)0 ± 079.6 ± 49.2
Week 12 (pre-dose)0 ± 087.1 ± 57.8
Week 12 (post-dose)252 ± 50.787.6 ± 49.7
Week 13 (pre-dose)62.4 ± 17.597.6 ± 68.6
Week 14 (pre-dose)56.6 ± 17.692.8 ± 68.0
Week 15 (pre-dose)64.2 ± 29.690.5 ± 59.1
Week 16 (pre-dose)68.8 ± 24.3103 ± 76.4
Week 17 (pre-dose)73.4 ± 30.892.1 ± 73.3
Week 18 (pre-dose)75.1 ± 27.195.0 ± 79.3
Week 21 (pre-dose)89.3 ± 40.072.9 ± 51.4
Week 28 (pre-dose)10.9 ± 12.016.0 ± 23.4
Week 32 (pre-dose)0.0663 ± 0.07050.189 ± 0.281
Week 36 (pre-dose)0.0110 ± 0.03300.0373 ± 0.0788
SecondaryNumber of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response
Time frame:
Up to Day 281
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response
ParticipantsArm 1 Combined Cohort A + B: Placebo to REGN4461Arm 2 Combined Cohort A + B: REGN4461 to REGN4461
Number of Participants With Treatment-emergent Anti-drug Antibody (ADA) Response00

Adverse events

Collected over From signing of informed consent up to day 281 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBTP Arm 1 Cohort A: Placebo0/6 (0%)1/6 (16.7%)6/6 (100%)
DBTP Arm 2 Cohort A: REGN44610/6 (0%)1/6 (16.7%)6/6 (100%)
DBTP Arm 1 Cohort B: Placebo0/4 (0%)1/4 (25%)4/4 (100%)
DBTP Arm 2 Cohort B: REGN44610/4 (0%)0/4 (0%)4/4 (100%)
SBTP Arm 1 Cohort A: Placebo to REGN44610/5 (0%)1/5 (20%)3/5 (60%)
SBTP Arm 2 Cohort A: REGN4461 to REGN44610/6 (0%)1/6 (16.7%)5/6 (83.3%)
SBTP Arm 1 Cohort B: Placebo to REGN44610/3 (0%)0/3 (0%)3/3 (100%)
SBTP Arm 2 Cohort B: REGN4461 to REGN44610/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventDBTP Arm 1 Cohort A: PlaceboDBTP Arm 2 Cohort A: REGN4461DBTP Arm 1 Cohort B: PlaceboDBTP Arm 2 Cohort B: REGN4461SBTP Arm 1 Cohort A: Placebo to REGN4461SBTP Arm 2 Cohort A: REGN4461 to REGN4461SBTP Arm 1 Cohort B: Placebo to REGN4461SBTP Arm 2 Cohort B: REGN4461 to REGN4461
Pancreatitis acuteGastrointestinal disorders1/60/61/40/40/50/60/30/4
HyperglycaemiaMetabolism and nutrition disorders0/60/60/40/41/50/60/30/4
Angina pectorisCardiac disorders0/60/60/40/40/51/60/30/4
Back painMusculoskeletal and connective tissue disorders0/61/60/40/40/51/60/30/4
HypertensionVascular disorders0/61/60/40/40/50/60/30/4
Most frequent other events
Showing 10 of 118
Most frequent other events
EventDBTP Arm 1 Cohort A: PlaceboDBTP Arm 2 Cohort A: REGN4461DBTP Arm 1 Cohort B: PlaceboDBTP Arm 2 Cohort B: REGN4461SBTP Arm 1 Cohort A: Placebo to REGN4461SBTP Arm 2 Cohort A: REGN4461 to REGN4461SBTP Arm 1 Cohort B: Placebo to REGN4461SBTP Arm 2 Cohort B: REGN4461 to REGN4461
SinusitisInfections and infestations0/60/60/40/41/50/60/33/4
DiarrhoeaGastrointestinal disorders2/60/61/40/40/50/62/31/4
COVID-19Infections and infestations1/62/61/42/40/51/61/30/4
Upper respiratory tract infectionInfections and infestations0/63/61/42/41/51/60/31/4
Abdominal painGastrointestinal disorders1/62/62/41/41/51/60/31/4
DizzinessNervous system disorders0/63/60/40/40/50/61/30/4
PainGeneral disorders0/60/60/40/40/50/60/32/4
Infusion related reactionInjury, poisoning and procedural complications0/61/60/42/40/52/60/30/4
Urinary tract infectionInfections and infestations0/60/61/40/42/52/61/30/4
HyperglycaemiaMetabolism and nutrition disorders0/61/60/40/42/50/60/30/4

Baseline characteristics

The double-blind safety analysis set (DB SAF) included all randomized participants who received any study drug during the double-blind treatment period (DBTP).

Age, Continuous
Age, Continuous(years)Arm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Total
Mean40.5 ± 16.7943.8 ± 13.4748.0 ± 11.9740.3 ± 12.8243.0 ± 13.40
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Total
Female563418
Male10102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Total
Hispanic or Latino00000
Not Hispanic or Latino664420
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Total
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White663318
More than one race00000
Unknown or Not Reported00101
Fasting Triglycerides Serum Concentration
Fasting Triglycerides Serum Concentration(milligrams per deciliter (mg/dL))Arm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Total
Geometric mean1100.9 (405 to 5681)737.8 (308 to 2487)675.0 (426 to 1534)336.2 (150 to 1376)698.3 (150 to 5681)
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(percentage of glycated hemoglobin)Arm 1 Cohort A: Placebo to REGN4461Arm 2 Cohort A: REGN4461 to REGN4461Arm 1 Cohort B: Placebo to REGN4461Arm 2 Cohort B: REGN4461 to REGN4461Total
Mean8.8 ± 1.628.2 ± 1.766.9 ± 0.918.6 ± 2.068.2 ± 1.68
08

Study locations

8 sites
  • Excel Medical Clinical Trials - A Flourish Research Site
    Boca Raton, Florida 33434, United States
  • National Institute of Health
    Bethesda, Maryland 20892, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • ICAN, Institute of Cardiometabolism and Nutrition
    Paris, 75013, France
  • Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo
    Santiago de Compostela, Galicia 15706, Spain
  • Ege University Faculty of Medicine
    Izmir, Bornova 35100, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Dec 2023, 21 months.

Results were first posted in Jul 2025, 1 year 6 months after primary completion. A results delay was requested in Nov 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Oct 22, 2021
StartActual
Feb 28, 2022
Primary completionActual
Dec 13, 2023
CompletionActual
Apr 18, 2024
Results delay requested
Nov 4, 2024
Results first posted
Jul 2, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05088460
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Feb 28, 2022
Primary completion
Dec 13, 2023
Completion
Apr 18, 2024
Results posted
Jul 2, 2025
Last update
Oct 16, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mibavademab

Start the discussion